Rasburicase in Patients at Risk for Tumor Lysis Syndrome
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Primary Objectives:
To determine the efficacy of rasburicase administered as a single dose followed by as needed
dosing (investigational arm) as compared to fixed dosing for 5 days (standard treatment arm)
in the treatment of patients at high risk or potential risk for tumor lysis syndrome.
Secondary Objectives:
1. To evaluate the plasma uric acid area under the curve (AUC) from baseline through 7 days
2. To evaluate the incidence of renal insufficiency and electrolyte abnormalities.
3. To determine the safety and immunogenicity of rasburicase.
4. To evaluate the cost-effectiveness of the experimental treatment (investigational arm).